Bioprosthetic Heart Valve Coating for Calcification Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional bioprosthetic heart valves are prone to stenosis, obstruction, and calcification, which limit their long-term durability and effectiveness in preventing blood flow issues.
Innovation Solution
A method involving a bioprosthetic heart valve coated with a therapeutic agent composition that inhibits stem cell attachment by activating nitric oxide production, using eNOS activators and anti-proliferative agents, applied to the valve and stent, combined with oral and intramuscular treatments to prevent calcification and stenosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bioprosthetic heart valves are used, then the valve can be implanted to replace diseased native valves, but the valves are prone to stenosis, obstruction, and calcification over time
Solution Approach 1:
The patent applies preliminary action by coating the bioprosthetic heart valve with therapeutic agents (eNOS activators and anti-proliferative agents) before implantation. This pre-treatment ensures that the valve is protected against calcification and stenosis from the moment of implantation, addressing the harmful effects before they can develop. The coating is applied to the valve tissue and/or stent structure in advance, so that when the valve is implanted, the therapeutic agents are already in position to inhibit stem cell attachment and bone formation.
Solution Approach 2:
The patent uses therapeutic agents as intermediaries between the bioprosthetic valve and the harmful biological processes of calcification. The eNOS activators and anti-proliferative agents act as mediators that interfere with the attachment of circulating stem cells to the valve surface and prevent their differentiation into bone-forming cells. This intermediary layer of medication blocks the harmful interaction between the valve material and the calcification process.
2Reliability
If the valve is coated with therapeutic agents, then stem cell attachment is inhibited and calcification is prevented, but the device complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical and biological properties of the valve surface through coating with therapeutic agents. The coating changes the surface characteristics to be less attractive to stem cells and introduces pharmacological activity that actively prevents calcification. The eNOS activators and anti-proliferative agents alter the biochemical environment around the valve, creating conditions that inhibit bone formation while maintaining valve function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively inhibits stenosis, obstruction, and calcification by preventing stem cell attachment and bone formation on the valve, extending the valve's functional lifespan and maintaining normal hemodynamics.
Implementation Method 1
activating nitric oxide production (i) in the circulating stem cells, (ii) in an endothelial cell lining covering the bioprosthetic heart valve tissue, or both
Implementation Method 2
treating the bioprosthetic heart valve with a tissue fixative
Implementation Method 3
eluting the coating composition from the elastical stent, one or more cusps, or both
Data Source
AI summary
Methods for inhibiting stenosis, obstruction and/or calcification of a heart valve following implantation in a vessel having a wall are disclosed. In one aspect the method includes providing a bioprosthetic heart valve mounted on an elastical stent; treating the bioprosthetic heart valve with a tissue fixative; coating the stent and the bioprosthetic valve with a coating composition including one or more therapeutic agents; implanting the bioprosthetic valve into the vessel in a diseased natural valve site; eluting the coating composition from the bioprosthetic valve; and inhibiting stenosis, obstruction and/or calcification of the bioprosthetic heart valve by preventing the attachment of stem cells to the bioprosthetic heart valve, the stem cells circulating external and proximate to the bioprosthetic heart valve by activating nitric oxide production (i) in the circulating stem cells, (ii) in an endothelial cell lining covering the bioprosthetic heart valve tissue, (iii) or both.